Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

BridgeBio Oncology Therapeutics, Inc.

Healthcare US BBOT

7.26USD
-0.52(6.68%)

Last update at 2026-06-09T20:00:00Z

Day Range

7.238.15
LowHigh

52 Week Range

8.0814.87
LowHigh

Fundamentals

  • Previous Close 7.78
  • Market Cap741.10M
  • Volume426171
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-145.53901M
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM 0.00000M
  • Diluted EPS TTM-4.3

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -134.04400M -74.27500M -64.69900M -0.00352M -0.04336M
Minority interest - - - - -
Net income -134.04400M -74.27500M -64.69900M -0.00352M -0.04336M
Selling general administrative 24.62M 7.76M 8.48M 0.00352M 0.07M
Selling and marketing expenses - - - - -
Gross profit -0.61000M - - - -
Reconciled depreciation 0.61M 0.21M 0.09M - -
Ebit - -80.86300M -64.77100M - -
Ebitda -145.81900M -80.65500M -64.67900M -0.00352M -0.04336M
Depreciation and amortization - 0.21M 0.09M - -
Non operating income net other - - - - -
Operating income -145.81900M -80.86300M -64.77100M -0.00352M -0.04336M
Other operating expenses 145.82M 80.86M 64.77M 0.00352M 0.04M
Interest expense - - - - -
Tax provision - - - - -
Interest income 11.34M 6.38M 0.07M - -
Net interest income 11.34M 6.38M 0.07M - -
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense - - - - -
Total revenue 0.00000M 0.00000M 0.00000M - -
Total operating expenses 145.82M 80.86M 64.77M 0.00352M 0.04M
Cost of revenue 0.61M - - - -
Total other income expense net 11.78M 8.18M 0.07M - 0.00000M
Discontinued operations - - - - -
Net income from continuing ops -134.04400M -74.27500M -64.69900M - -
Net income applicable to common shares - - - - -
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 448.38M 194.42M 0.33M 0.14M 0.14M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets -0.38600M 0.25M 1.96M - -
Total liab 37.28M 5.71M 0.40M 0.17M 0.16M
Total stockholder equity 411.10M 188.72M -0.06357M -0.02188M -0.01836M
Deferred long term liab - - - - -
Other current liab 33.15M 0.19M 0.33M 0.12M 0.13M
Common stock 0.00800M 192.45M 0.00046M 0.00029M 0.00029M
Capital stock 0.00800M 0.00000M 0.00000M - -
Retained earnings -356.56700M -3.73312M -0.08857M -0.04688M -0.04336M
Other liab - - - - -
Good will - - - - -
Other assets - - - - -
Cash 373.69M 1.70M 0.25M - -
Cash and equivalents - - - - -
Total current liabilities 35.04M 0.19M 0.40M 0.17M 0.16M
Current deferred revenue - - - - -
Net debt -370.92100M -1.69778M 0.07M 0.04M 0.04M
Short term debt 0.52M - 0.07M 0.04M 0.04M
Short long term debt - - - - -
Short long term debt total 2.77M - 0.07M 0.04M 0.04M
Other stockholder equity 767.64M - 0.02M 0.02M 0.02M
Property plant equipment - - - - -
Total current assets 425.46M 1.95M 3.94M - -
Long term investments - - - - -
Net tangible assets - - - - -
Short term investments 51.77M 124.78M 0.00000M - -
Net receivables 0.39M - - - -
Long term debt - - - - -
Inventory - - - - -
Accounts payable 1.37M 3.07M 0.57M - -
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 0.02M - - - -
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 22.79M 0.03M 0.33M 0.14M 0.14M
Deferred long term asset charges - - - - -
Non current assets total 22.92M 192.47M 0.33M 0.14M 0.14M
Capital lease obligations 2.77M 0.00000M - - -
Long term debt total - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments 73.93M -120.53000M -2.82000M - -
Change to liabilities - - - - -
Total cashflows from investing activities 73.33M -184.00000M - - -
Net borrowings - - - - -
Total cash from financing activities 383.40M 186.46M 55.12M - -
Change to operating activities - - - - -
Net income -134.04400M 7.60M -0.04169M -0.00352M -0.00007M
Change in cash 342.84M 1.70M 0.23M - -
Begin period cash flow 30.98M 0.25M 0.03M - -
End period cash flow 373.82M 1.70M 0.25M 0.03M -
Total cash from operating activities -113.89400M -0.76382M -52.07900M - -
Issuance of capital stock 22.22M 206.24M 55.12M - -
Depreciation 0.61M 0.21M 0.09M - -
Other cashflows from investing activities - - - - -
Dividends paid - - - - -
Change to inventory - - - - -
Change to account receivables - - - - -
Sale purchase of stock - - - - -
Other cashflows from financing activities -12.32200M -0.57855M - - -
Change to netincome - - - - -
Capital expenditures 0.61M 0.05M 0.41M 0.00000M 0.00000M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 6.43M -0.10461M 0.01M - -
Stock based compensation 5.87M 0.27M 16.46M - -
Other non cash items 7.23M -8.53029M 0.03M 0.00352M 0.00007M
Free cash flow -114.50000M -0.76382M -52.49300M - -

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x)
BBOT
BridgeBio Oncology Therapeutics, Inc.		 -0.52 6.68% 7.26 - - - 1.80
NVO
Novo Nordisk A/S		 1.17 2.85% 42.19 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 0.35 0.85% 41.60 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 2.81 0.63% 445.77 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 4.84 0.79% 616.18 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

BridgeBio Oncology Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of small-molecule therapeutics for the treatment of renin-angiotensin system and phosphoinositide 3-kinase malignancies in the United States. The company develops BBO-8520, an orally bioavailable small molecule direct inhibitor, which is in Phase I clinical trial for the treatment of patients with KRASG12C mutant non-small cell lung cancer; and BBO-11818, an orally bioavailable small molecule pan-KRAS inhibitor, which is in Phase I clinical trial for the treatment of patients with KRAS G12D and KRAS G12V cell-derived xenograft models. It is also involved in the development of BBO-10203, an orally bioavailable small molecule, which is in Phase I clinical trial for the treatment of patients with HER2+ breast cancer, HR+/HER2- breast cancer, KRAS mutant colorectal cancer, and KRAS mutant non-small cell lung cancer; and precision oncology assets for patients with tumors. The company was incorporated in 2016 is headquartered in South San Francisco, California.

BridgeBio Oncology Therapeutics, Inc.

256 East Grand Avenue, South San Francisco, CA, United States, 94080

Key Executives

Name Title Year Born
Mr. Eli M. Wallace Ph.D. CEO & Director 1968
Dr. Pedro J. Beltran M.D., Ph.D. Chief Scientific Officer 1971
Dr. Yong Ben M.B.A., M.D. Chief Medical & Development Officer 1974
Mr. Uneek Mehra M.B.A. Chief Financial Officer 1973
Mr. Howard Y. Chang M.D., Ph.D. Vice President of Operations NA
Mr. Aaron Chan J.D. Vice President of Legal NA
Ms. Angela Peters Senior Vice President of People NA
Mr. Idan Elmelech M.A., M.B.A. Senior VP of Strategy & Business Development NA
Mr. Bin Wang Ph.D. Senior Vice President of Drug Discovery NA
Mr. Daniel Watson Ph.D. Senior Vice President of Chemistry, Manufacturing & Controls NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions